AMGN vs GILD
Amgen and Gilead Sciences, both Healthcare
Amgen is the larger company at $237B against $194B. Over the past year AMGN returned +52% against +35% for GILD. The RyuScore puts AMGN ahead, 62 against 44 out of 100.
| Figure | AMGN | GILD |
|---|---|---|
| Last close | $439 | $156 |
| Market cap | $237B | $194B |
| Trailing P/Elower is cheaper for the same earnings, not automatically better | 27.3 | n/a |
| Dividend yield | 2.2% | 2.1% |
| 1-year return | +52% | +35% |
| 5-year return | +147% | +172% |
| RyuScoresector-relative, 1–10 | 62/100 | 44/100 |
Figures from SEC filings and end-of-day closes. Highlighting marks the higher or lower number, which is not the same as the better investment, a low P/E can be a warning and a high one can be deserved.
Amgen
Revenue of $10B in Q2 2026, net income $2.4B. Its largest reported line is Other Products, 17% of the disclosed total.
Gilead Sciences
Revenue of $7.8B in Q2 2026, net income null. Its largest reported line is HIV Product Sales, 55% of the disclosed total.
Open these two in the interactive comparison to add more names, change the period or see the correlation.